Seeking Alpha

Alexion Pharmaceuticals' (ALXN) Soliris gets Orphan Drug Designation for the treatment of the...

Alexion Pharmaceuticals' (ALXN) Soliris gets Orphan Drug Designation for the treatment of the rare neurological disorder neuromyelitis optica for which there are no approved treatments. The drug "significantly" reduced relapse frequency in a Phase 2 study. Last month, SA contributor Todd Campbell predicted that "additional Soliris indications [could] support future sales growth." (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|